Board of Directors
Company Risk
A shortage of key personnel in critical professions directly related to the Group's business products and services may affect customer confidence, business operational continuity, as well as competitiveness and the company's long-term revenue.
In the future, the Group will implement projects for the in-house training of scientists and medical technologists. The Group will recruit medical technologists from various universities and host an Open House project, providing opportunities for medical technology students to attend seminars and visit the company's actual laboratories. This will include presentations on embryo culture knowledge and operational procedures delivered by the company's knowledgeable and expert scientists. This initiative aims to build brand awareness and credibility for the company, thereby attracting high-quality personnel in the future. Furthermore, in the long term, the Group plans to offer scholarships for suitable specialized scientific professions as part of its talent pipeline development process. These efforts will mitigate the risk of long-term shortages of specialized personnel and ensure continuity in efficient human resource management.
If the Group is unable to comply with the laws and regulations of the relevant regulatory authorities, this may result in the relevant regulatory authorities considering the suspension or revocation of licenses, or the non-renewal of licenses for the Group. This could impact the Group's operations, as well as incur various expenses required for rectification, improvement, and bringing operations back into compliance, and also affect the organization's reputation and image.
In the past, the Group has been able to comply with established standards and has successfully obtained or maintained the necessary business licenses within the stipulated periods. There has never been any cause for the revocation of the Group's business licenses. Furthermore, the Group has established an internal department responsible for coordinating with government agencies and external regulatory bodies to obtain renewals or registrations of relevant licenses, as well as closely monitoring changes in regulations, rules, and laws pertinent to the Group. Additionally, the Group provides knowledge enhancement programs for management and employees on critical issues, including monitoring and auditing all related operational processes to ensure that the Group conducts its business in accordance with regulations, rules, laws, and relevant requirements appropriately and correctly.
If unable to adapt to changes in treatment technology, the Group may not be able to meet customer demands, and customer decisions may change, which could impact the Group's financial position and operating performance.
The Group of Companies focuses on and prioritizes the quality of analytical testing and medical services provided to its clients through the use of efficient and safe medical instruments. These instruments are exclusively certified by the U.S. Food and Drug Administration (USFDA) and the Thai Food and Drug Administration (FDA), as these are considered the highest safety standards. The Group of Companies procures medical equipment and instruments from world-renowned distributors who are certified to these standards. These distributors also consistently provide information and collaborative learning opportunities regarding new products and technologies to the Group of Companies, enabling it to understand and prepare plans to address changes in medical treatment technology at all times. Should there be changes in treatment technology, the Group of Companies will conduct studies to understand these changes, the anticipated benefits, and the cost-effectiveness of investment before formulating a capital expenditure plan to acquire new technological medical equipment and instruments as replacements. Furthermore, the Group of Companies continuously monitors information and news regarding technological advancements by encouraging relevant personnel to regularly participate in international academic conferences. New innovation data is also reported to the Board of Directors or relevant committees to ensure that the Group of Companies can always adapt to changes in medical treatment technology, instruments, and equipment.
Over-reliance on a single medical professional may cause the company to lose opportunities to build brand recognition with customers, potentially resulting in the loss of future customers and a disruption in revenue growth if customers do not trust other medical professionals.
The Group of Companies has recognized potential risks. In the past, the Group has developed the GFC brand to be more credible and widely recognized, moving away from a presentation model reliant on a single physician. Other physicians have been encouraged to play a role in driving the organization, for instance, by appearing in media to educate the public through online channels and organizing academic activities led by physicians and scientists to enhance public awareness. Data from the number of service recipients in the past period indicates a continuous increase in patients receiving treatment from physicians who are not the primary relied-upon physician. For the group of embryologists, the Group of Companies promotes scientists to acquire knowledge, expertise, and international certification, ensuring a continuous supply of personnel who can grow in their careers or reach a level comparable to Ms. Piyada Wiratpong. Furthermore, the Group regularly conducts in-house training programs for scientists to support future business expansion and manage the risk of over-reliance on individual personnel, thereby fostering sustainable future growth. [image]
Over-reliance on a single business partner may affect business continuity if the partner is unable to deliver medicines and medical supplies according to the specified quantity and timeframe. Furthermore, it may lead to missing opportunities to benefit from fair and competitive prices for medicines and medical supplies. This could result in limitations in managing service costs or operational costs, consequently impacting the company's financial position and operational performance in the long term.
The Group has recognized the risk associated with relying on such distributors. Therefore, it has a policy to procure pharmaceutical products and medical supplies from domestic manufacturers or authorized distributors of foreign manufacturers that meet the Group's standards. An Approved Vendor List for pharmaceutical and medical supply companies is maintained, with consideration given to several factors such as licenses and standard certifications, approval from the U.S. Food and Drug Administration (USFDA) and the Thai Food and Drug Administration (FDA), the ability to supply quality pharmaceutical products and medical supplies, reputation, physician demand, and the product delivery system to the Group, among others. There are no specific contracts or obligations regarding the procurement of pharmaceuticals, medical supplies, medical materials, and medical devices with any particular vendor. The Group is confident that it can manage the risk of relying on distributors of pharmaceutical products, medical supplies, and laboratory reagents. This is because the Group has maintained good relationships with the manufacturers of these pharmaceuticals, medical supplies, and laboratory reagents. In 2025, a Procurement Committee was appointed, responsible for establishing the company's procurement policies and related guidelines, evaluating and selecting suitable vendors or contractors, overseeing and monitoring the procurement process to ensure compliance with procedures, and regularly reporting to management. Concurrently, the procurement department and relevant units systematically control and monitor procurement operations, ensuring they are auditable. Furthermore, the Group has not experienced any issues with ordering or shortages of these pharmaceutical products, medical supplies, and laboratory reagents in the past. In addition, the Group maintains good relationships with key distributors in the market, enabling it to procure pharmaceuticals and medical supplies from other distributors besides those mentioned above. Moreover, most distributors are merely agents and not direct manufacturers of pharmaceutical products and medical supplies. Therefore, pharmaceutical products and medical supplies can be procured from alternative distributors without affecting transition costs or incurring any opportunity losses.
Being sued by service recipients or related stakeholders affects the organization's credibility, image, and reputation, as well as various expenses for potential legal proceedings or litigation, and the long-term sustainability of the company.
Given the aforementioned risks, the Group has clear plans and procedures to prevent the occurrence of the various incidents mentioned above. The Group has established service processes that must comply with relevant standards and criteria, which are under the supervision of the Ministry of Public Health, the Medical Council, and the service standards related to medical assisted reproductive technology as per the Act on the Protection of Children Born by Assisted Reproductive Technology B.E. 2558 (2015). Throughout the past, the Group's medical personnel have strictly adhered to the prescribed standards. Furthermore, prior to every service, the Group requires service recipients to sign a consent form for all treatment steps, in accordance with the Medical Council's regulations. This ensures that service recipients and their spouses are informed of the service procedures, success rates, precautions, and potential risks associated with the services. After receiving services from the Group, service recipients are asked to evaluate their satisfaction with the services and treatments received, in order to assess service quality and operational efficiency. This serves to develop and improve the Group's services and also acts as a measure to prevent the risk of lawsuits claiming damages. Furthermore, should complaints arise or service recipients express dissatisfaction with the services provided, the Group has policies and procedures in place to address them according to the severity of the situation, such as actions taken by relevant nurses, doctors, the marketing department, and senior management, among others. Additionally, in 2025, a Quality Committee was appointed with the role and responsibility to oversee, supervise, and develop the quality of services and work processes to comply with international standards and relevant professional standards, as well as to establish an incident reporting process within the organization. This promotes a culture of continuous operational performance improvement to ensure accurate and timely reporting and communication of information, as well as genuine root cause analysis to prevent recurring errors, and to define preventive measures to systematically and effectively reduce potential risks. This also helps elevate the quality of services and treatment, prevent and mitigate long-term negative impacts, and build confidence among stakeholders in all sectors. As of December 31, 2025, the Group has not faced any significant lawsuits claiming damages from medical treatment and/or services.
May incur liability for withholding income tax and tax surcharges, as well as other relevant taxes, should there be differing interpretations of tax law concerning the classification of such medical remuneration income. This would impact the company's operational performance and corporate image and reputation.
The Group of Companies engaged a tax advisor to assess the correctness of the nature of income for which the Group of Companies pays professional fees to medical practitioners. The tax advisor has provided an opinion that these items constitute income under Section 40(6) of the Revenue Code, consistent with the Group of Companies' current practice. Furthermore, to mitigate the impact of future tax risk factors, the Group of Companies has stipulated in its contracts with medical personnel that the medical practitioners shall be responsible for any expenses that may arise from additional tax assessments imposed on the Group of Companies due to individual doctors' withholding tax matters.
Economic fluctuations impact consumer purchasing power and decision-making, consequently affecting cash flow in business operations and revenue growth, which may not align with predetermined targets.
However, the revenue of this business significantly depends on the standard of service and treatment, and the success rate. This leads the Group to develop service quality, elevate treatment in various stages, and invest in new technologies that will help increase the success rate. This is coupled with formulating strategies to build business partnerships with major private hospital groups to create and attract new customer segments and establish a competitive advantage for long-term revenue and profit margin growth, as well as adapting marketing strategies to align with rapidly changing situations. Furthermore, the Group continues to identify opportunities among international clients, which remains a high-potential market. Therefore, marketing efforts are focused on attracting this customer segment to increase service utilization, both in 2025 and continuously into 2026. Moreover, the infertility treatment service business has growth opportunities in the future due to more flexible adjustments to relevant regulations, particularly China's pro-natalist policies, the enforcement of the Equal Marriage Act, and the preparation to amend Thailand's surrogacy laws. In addition, this includes the growing global trend of egg freezing. With GFC Group's strengths in knowledgeable, capable, and specialized personnel, especially the team of doctors, nurses, and embryologists, reflected by a treatment success rate that remains above standard, these factors will continue to be the Group's strengths, enhancing its competitive potential and continuously generating growing revenue in the next period.
Shareholder Risk
This may slow down strategic decision-making if opinions diverge, particularly if the major shareholder group disagrees. Conversely, decisions may be made quickly if opinions align with the major shareholder group. However, issues or concerns may arise during voting due to the control of power by the majority, which might be perceived as lacking sufficient transparency. Furthermore, presenting issues from the minority may prove difficult to gain approval, especially if the matters under discussion involve major stakeholders.
The Group recognizes the importance of balancing power, and therefore has clearly and transparently defined the scope of authority and responsibilities of its various committees. Measures have been established for related party transactions involving directors, major shareholders, executives, controlling persons, and individuals who may have conflicts of interest, whereby such individuals shall not have the right to vote on the approval of such transactions. This also includes the establishment of an independent audit committee to participate in the Group's board of directors, for transparency and to assure shareholders that they can review operations and maintain a certain level of checks and balances as representatives of minority shareholders. Furthermore, it assists in scrutinizing various matters before presenting them to the shareholders' meeting. The Group's board structure comprises independent directors accounting for more than half of the total number of directors of the Group. (1) (A total of 4 independent directors out of 9 total directors of the Group.) Furthermore, once the Group is listed on the Stock Exchange of Thailand, it must disclose information and comply with the relevant rules and regulations of the Securities and Exchange Commission (SEC) and the Stock Exchange of Thailand (SET), such as related party transactions and the acquisition and disposal of the Group's assets, etc., for the utmost benefit of the Group and its shareholders. (1) Two independent directors, Ms. Karndee Leopairote and Mr. Ek Bhadra-thanakul, have submitted their resignations from their positions as company directors, effective December 16, 2025.
The market price of the Company Group's ordinary shares may fluctuate according to market conditions due to uncontrollable factors, which may result in investors being unable to sell the Company Group's shares at the anticipated price, or they may be traded at a price lower than the offering price of the Company Group's ordinary shares.
The company continuously evaluates economic conditions, industry, and related markets to formulate annual strategies and business plans. Furthermore, it monitors the movements of various factors that may impact the performance of the group of companies, enabling timely decisions to adjust strategies, operational plans, and response approaches.
Unlock full benchmarking
Claim this company to see every KPI your sector qualifies for, from 70+ across the market, benchmarked against sector peers.

